Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

HK regulator says Alibaba broke takeover rules with 'special deal'

Published 05/18/2016, 10:29 AM
Updated 05/18/2016, 10:30 AM
© Reuters. A sign of Alibaba Group is seen at CES Asia 2016 in Shanghai

© Reuters. A sign of Alibaba Group is seen at CES Asia 2016 in Shanghai

By Elzio Barreto

HONG KONG (Reuters) - Hong Kong's securities regulator said that Chinese e-commerce giant Alibaba Group Holding Ltd (N:BABA) breached takeover rules in the purchase of a healthcare firm in 2014 because it also bought a company owned by the brother of the healthcare firm's vice chairman on "favourable terms."

Alibaba agreed to buy a stake in CITIC 21CN, now known as Alibaba Health Information Technology Ltd (HK:0241), for $170 million two years ago.

During the acquisition process, Alibaba also agreed to buy Hebei Huiyan Medical Technology Co from Chen Wen Xin, who was also a shareholder of CITIC 21CN and is the younger brother of the company's vice chairman, Chen Xiao Ying.

Hong Kong's Takeovers and Mergers Panel, part of the Securities and Futures Commission (SFC), ruled that Alibaba's purchase of Hebei Huiyan "constituted a special deal with favourable conditions which were not extended to all shareholders and was a clear breach of the Takeovers Code," according to the decision published on Wednesday.

Alibaba has already said it may appeal the panel's decision, which was announced last month without the full details.

The company said on Wednesday it is reviewing the panel's ruling and that it believes it has complied with the takeover code.

In calling the purchase of Hebei Huiyan a "special deal" the SFC invoked a rule aimed at preventing unequal treatment of shareholders. Alibaba said a 533 percent surge in Alibaba Health shares since its takeover benefited shareholders of the health unit.

"Therefore, we believe that no Alibaba Health shareholder has been unfairly affected," Alibaba said in an emailed statement.

The SFC ruled that the breach of code in the 2014 investment meant an original waiver to a requirement to launch a general offer to all investors was invalidated, Alibaba said last month.

But the e-commerce firm added the regulator issued a new waiver in view of the sharp rise in Alibaba Health stock since 2014, meaning Alibaba is not currently required to launch a full buyout.

© Reuters. A sign of Alibaba Group is seen at CES Asia 2016 in Shanghai

Alibaba owns 38 percent of Alibaba Health, but last year injected an online pharmacy business into Alibaba Health. Once that transaction is approved, it will own a 53 percent stake.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.